High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses

B-RAF Mutant Alleles Associated with Langerhans Cell Histiocytosis, a Granulomatous Pediatric Disease

(2012) Takeshi Satoh et al.   PLoS One

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

(2011) David Capper et al.   ACTA NEUROPATHOLOGICA

Association d’une histiocytose langerhansienne à une maladie d’Erdheim-Chester

(2011) A. Marchal et al.   ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE

CNS involvement and treatment with interferon-  are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients

(2011) L. Arnaud et al.   BLOOD

Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients

(2011) L. Arnaud et al.   BLOOD

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recurrent BRAF mutations in Langerhans cell histiocytosis

(2010) G. Badalian-Very et al.   BLOOD

Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis

(2008) J. Haroche et al.   BLOOD

Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000–2004

(2008) Aurélie Guyot-Goubin et al.   PEDIATRIC BLOOD & CANCER